Biomind Labs Inc (BMND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomind Labs Inc (BMND) has a cash flow conversion efficiency ratio of 0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-48.96K ≈ $-35.42K USD) by net assets (CA$-1.74 Million ≈ $-1.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biomind Labs Inc book value and equity for net asset value and shareholders' equity analysis.
Biomind Labs Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Biomind Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomind Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomind Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HYDROTOR SA
WAR:HDR
|
0.017x |
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
0.004x |
|
Agrogeneration
PA:ALAGR
|
-0.030x |
|
Argentina Lithium & Energy Corp
V:LIT
|
-0.020x |
|
HYTN INNOVATIONS INC.
F:85W0
|
0.029x |
|
BSL Corp Bhd
KLSE:7221
|
0.024x |
|
Energy Action Ltd
AU:EAX
|
-0.017x |
|
Mint Incorporation Limited Class A Ordinary Shares
NASDAQ:MIMI
|
N/A |
Annual Cash Flow Conversion Efficiency for Biomind Labs Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Biomind Labs Inc from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see BMND stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-1.74 Million ≈ $-1.26 Million |
CA$-67.55K ≈ $-48.86K |
0.039x | -85.72% |
| 2024-12-31 | CA$-1.30 Million ≈ $-940.54K |
CA$-354.43K ≈ $-256.39K |
0.273x | -49.03% |
| 2023-12-31 | CA$-1.43 Million ≈ $-1.04 Million |
CA$-765.93K ≈ $-554.06K |
0.535x | -93.84% |
| 2022-12-31 | CA$-247.66K ≈ $-179.15K |
CA$-2.15 Million ≈ $-1.56 Million |
8.685x | +997.29% |
| 2021-12-31 | CA$2.19 Million ≈ $1.59 Million |
CA$-2.12 Million ≈ $-1.54 Million |
-0.968x | -- |
About Biomind Labs Inc
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical… Read more